A newsletter for the Highmark Blue Shield providers in central Pennsylvania, the Lehigh Valley, northeastern Pennsylvania and southeastern Pennsylvania
Issue 10, October 2023
The Centers for Disease Control and Prevention (CDC) has recently approved new, single-dose COVID-19 booster vaccines from Pfizer, Moderna, and Novavax to protect against the XBB variant. The Pfizer and Moderna boosters are for all persons 6 months and older; the Novavax vaccine is for individuals 12 and older. For more information, click here
.
Highmark is now accepting 275 attachments from facilities and providers who are responding to a request for additional documentation. Providers should submit 275 transactions through their trading partners via Electronic Data Interchange (EDI). To learn more, click to read the Special Bulletin.
The Centers for Disease Control and Prevention (CDC) has approved respiratory syncytial virus (RSV) vaccines for infants, pregnant women, and adults 60 years of age and older. These vaccines are being retroactively added to the Highmark Preventive Schedules. Click hereto read the updated Special Bulletin.
To align with our internal claim review process, Highmark will start using a clinical editing tool to analyze Federal Employee Program (FEP) claims, effective December 1, 2023. Clinical editing is an effective and efficient method for quickly reviewing and approving correct claims, while also identifying errors on incorrectly coded claims during the prepayment process. To learn more, click here.
There was a typing error in the September 4, 2023, published version of S-248 Nerve Ablation and Injection. The Genicular Nerve Block section of the policy was inadvertently placed into the Genicular Nerve Radiofrequency Ablation section. The policy has been corrected and published on September 27, 2023.
The October newsletter is available here.
